Alcohol-Induced Disorders: Clinical Trials

302 trials for Alcohol-Induced Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

151 completed, 47 unknown, 46 recruiting, 22 terminated. 108 Not applicable, 53 Phase 2, 30 Phase 3, 18 Phase 4, 16 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable108Completed 55, Recruiting 22, Unknown 12, Terminated 7, Not yet recruiting 5, Active not recruiting 4, Withdrawn 2, Enrolling by invitation 1
Phase 253Completed 29, Recruiting 7, Terminated 6, Withdrawn 4, Not yet recruiting 3, Unknown 3, Active not recruiting 1
Phase 330Completed 15, Recruiting 5, Unknown 5, Terminated 3, Active not recruiting 1, Withdrawn 1
Phase 418Unknown 8, Completed 7, Terminated 2, Suspended 1
Phase 116Completed 11, Unknown 3, Not yet recruiting 1, Terminated 1
Early Phase 16Completed 3, Recruiting 1, Terminated 1, Withdrawn 1

Follow Alcohol-Induced Disorders: new trials by email Literature Review of Alcohol-Induced Disorders trials Research Report on Alcohol-Induced Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pomegranate Dietary Supplements in AUD and ALD
Pomegranate Dietary Ssupplement - Alcohol Use Disorder, Alcohol-associated Liver Disease
Not yet recruitingUniversity of Louisville1442027-01-012026-07-24
Inflammatory and Neuroimmune Guided Investigation of Underlying Fatigue in Patients With Cirrhosis
Cirrhosis Alcoholic, Fatigue Symptom
Not yet recruitingKing's College London502027-01-012026-10-27
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)
ALN-CIDEB, Placebo - Alcohol-Associated Liver Disease, ALD
Phase 2Not yet recruitingRegeneron Pharmaceuticals1202026-12-092026-11-12
Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care
Preventox, a digital self-help tool for patients with intoxications in intensive care., Preventox control group - Intoxication, Delirium Tremens (DTs)
Not applicableNot yet recruitingKarolinska Institutet502026-09-302026-09-23
Elastography-based Brief Alcohol Intervention in Hospitalized Individuals
Elastography-based brief alcohol intervention - Alcoholic Liver Disease (ALD), Alcohol Use Disorder
Not applicableRecruitingOslo University Hospital5002026-09-142026-10-22
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Efimosfermin alfa, Placebo - Liver Diseases, Alcoholic
Phase 2RecruitingGlaxoSmithKline2742026-08-312026-11-12
Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease
PEth Based Contingency Management, PEth Monitoring with Fixed Incentives - Alcohol Use Disorder, Alcohol-associated Liver Disease
Not applicableNot yet recruitingMassachusetts General Hospital902026-08-012026-03-12
A-TANGO Phase 2 Study
Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis
Phase 2RecruitingYaqrit Ltd782026-06-292026-09-21
CARRII Native Intervention Optimization Trial
CARRII Native Cores - Fetal Alcohol Spectrum Disorders, Pregnancy
Not applicableRecruitingUniversity of Virginia5122026-06-022026-06-23
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
N-Acetylcysteine (NAC) Treatment, Prednisolone, Placebo of N-acetylcysteine - Alcoholic Hepatitis
Phase 3RecruitingUniversity Hospital, Lille4772026-05-222026-06-01
The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)
Palm Tocotrienol Rich Fraction (TRF), Refined, bleached, and deodorised (RBD) palm olein - Alcoholic Fatty Liver Disease
Phase 2Not yet recruitingUniversiti Kebangsaan Malaysia Medical Centre262026-05-022026-04-29
Thrive Person-Centered Planning Program for Young Adults With Fetal Alcohol Spectrum Disorders
Thrive Program - Fetal Alcohol Spectrum Disorders
Not applicableRecruitingUniversity of Rochester602026-04-142026-04-30
Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease
Individually Targeted rTMS, Conventional rTMS, Transcranial Magnetic Stimulation Sham - Liver Diseases, Alcoholic, Fatty Liver
Not applicableNot yet recruitingThe Affiliated Hospital of Hangzhou Normal University1052026-02-012026-02-10
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
Larsucosterol, Placebo - Hepatitis
Phase 3RecruitingBausch Health Americas, Inc.3502026-01-292026-11-12
Alcohol Consumption and Plasma cfDNA Methylation in Chronic Hepatitis B
Alcohol Consumption - Chronic Hepatitis B, Alcoholic Hepatitis
CompletedBeijing Municipal Administration of Hospitals852025-11-212026-10-08
Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial
Offer of specialized alcohol use disorder treatment in the hepatology clinic - Liver Diseases, Alcoholic, Alcohol Use Disorder
Not applicableRecruitingZealand University Hospital2212025-11-152025-11-18
LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis
TREM-1 expression (via immunohistochemistry) between SAH patients and controls - Severe Alcoholic Hepatitis
Not yet recruitingCentral Hospital, Nancy, France3002025-10-012025-09-16
Long-term Sustainability of the Effects of Dog-Assisted Therapy in Children and Adolescents With Fetal Alcohol Spectrum Disorder: a 12-month Longitudinal Study
Dog assisted therapy - Fetal Alcohol Effect, Fetal Alcohol Syndrome
Not applicableActive not recruitingHospital Universitari Vall d'Hebron Research Institute552025-09-012026-07-21
Health Literacy and Self-efficacy Expectations in Patients With Alcohol-related Liver Cirrhosis
Self-Efficacy, Health Literacy
RecruitingHannover Medical School2002025-08-112025-09-11
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Not applicableRecruitingPhenomen Pharma902025-06-192025-07-23

Showing 20 of 302. Sign in to see all of them.

Narrower conditions

Hepatitis, Alcoholic (109)  ·  Liver Diseases, Alcoholic (74)  ·  Fetal Alcohol Spectrum Disorders (65)  ·  Liver Cirrhosis, Alcoholic (45)  ·  Alcoholism (37)  ·  Fibrosis (29)  ·  Liver Cirrhosis (25)  ·  Liver Diseases (17)  ·  Non-alcoholic Fatty Liver Disease (14)  ·  Alcohol Withdrawal Delirium (11)  ·  Hepatitis (8)  ·  Carcinoma, Hepatocellular (7)  ·  Fatty Liver (7)  ·  Fatty Liver, Alcoholic (7)

Broader conditions

Chemically-Induced Disorders (302)  ·  Substance-Related Disorders (300)  ·  Alcohol-Related Disorders (296)  ·  Digestive System Diseases (214)  ·  Liver Diseases (193)  ·  Liver Diseases, Alcoholic (134)  ·  Hepatitis (109)  ·  Pathological Conditions, Signs and Symptoms (96)  ·  Pathologic Processes (89)  ·  Urogenital Diseases (73)  ·  Female Urogenital Diseases and Pregnancy Complications (71)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (68)  ·  Fetal Diseases (65)  ·  Pregnancy Complications (64)

Interventions

Prednisolone (11)  ·  Ethanol (9)  ·  Pentoxifylline (9)  ·  Blood Specimen Collection (7)  ·  Granulocyte Colony-Stimulating Factor (7)  ·  Acetylcysteine (6)  ·  Choline (6)  ·  Baclofen (5)  ·  Fecal Microbiota Transplantation (5)  ·  Liver Transplantation (4)  ·  Prednisone (4)  ·  Probiotics (4)  ·  Standard of Care (4)  ·  Adrenal Cortex Hormones (3)  ·  Cognitive Training (3)

Sponsors

Institute of Liver and Biliary Sciences, India (11)  ·  University of Rochester (9)  ·  University Hospital, Lille (8)  ·  Erasme University Hospital (7)  ·  University of Aarhus (7)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  Indiana University (6)  ·  The Cleveland Clinic (6)  ·  University of Oklahoma (6)  ·  Chuncheon Sacred Heart Hospital (5)  ·  Pharmicell Co., Ltd. (5)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (5)  ·  Centers for Disease Control and Prevention (4)  ·  Hospital Universitari Vall d'Hebron Research Institute (4)  ·  Mayo Clinic (4)

Countries

United States (117)  ·  France (38)  ·  India (23)  ·  Denmark (19)  ·  United Kingdom (18)  ·  South Korea (15)  ·  Canada (13)  ·  Spain (11)  ·  Belgium (10)  ·  China (7)  ·  Germany (6)  ·  Australia (4)  ·  Finland (4)  ·  Italy (4)  ·  Mexico (4)

Top investigators

Jeffrey R Wozniak, Ph.D. (4)  ·  Michael J Vinikoor, MD (3)  ·  Arnaud Lemmers, MD (2)  ·  Christophe Moreno, MD, PhD (2)  ·  Craig J McClain, MD (2)  ·  Hanna Kahila, MD (2)  ·  Karen S Ingersoll, Ph.D. (2)  ·  Ki Tae Suk, PhD (2)  ·  Moonyoung Kim (2)  ·  Naga Chalasani, MD (2)  ·  Philippe Mathurin, MD,PhD (2)  ·  Robert S Brown, MD, MPH (2)  ·  Santiago Tome, MD (2)  ·  Soon Koo Baik, M.D.,Ph.D (2)

Results publications

PMID 37011138, PMID 16026887, PMID 19553649, PMID 31811953, PMID 35084335, PMID 38215876, PMID 39956364, PMID 10782906, PMID 11113085, PMID 11172350, PMID 11605686, PMID 11943418, PMID 14647046, PMID 14653766, PMID 15122768, PMID 1531090, PMID 15349802, PMID 15618643, PMID 15763232, PMID 16009691, PMID 17204261, PMID 17518367, PMID 18068515, PMID 18218147, PMID 18270828, PMID 1828447, PMID 18721242, PMID 19058754, PMID 19177575, PMID 19340904, PMID 19445945, PMID 19459039, PMID 19560604, PMID 19821406, PMID 20334708, PMID 20375733, PMID 20561703, PMID 20944765, PMID 20951277, PMID 21085006, PMID 21334404, PMID 2142869, PMID 21838526, PMID 22044287, PMID 22070475, PMID 22251828, PMID 22388710, PMID 22633836, PMID 22821948, PMID 22898443

NIH funding

U01AA026104 (3), 2025 (2), P50AA027054 (2), R01AA016234 (2), R01AA024123 (2), U01AA021788 (2), U01AA021840 (2), U01AA021886 (2), U01AA021891 (2), U01AA021893 (2), U24DK130164 (2), 2004 (1), 2014 (1), 2016 (1), F31AA031596 (1)